Aligning opportunity cost and net benefit criteria: the health shadow price

被引:0
作者
Eckermann, Simon [1 ]
机构
[1] Univ Wollongong, Sch Hlth & Soc, Wollongong, NSW, Australia
关键词
opportunity cost; net benefit; threshold value; health shadow price; budget constrained optimization; allocative efficiency; displacement efficiency; 24-HOUR MOVEMENT GUIDELINES; SEDENTARY BEHAVIOR; PHYSICAL-ACTIVITY; UNCERTAINTY; INTEGRATION; DECISIONS;
D O I
10.3389/fpubh.2024.1212439
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Given constrained healthcare budgets and many competing demands, public health decision-making requires comparing the expected cost and health outcomes of alternative strategies and associated adoption and financing actions. Opportunity cost (comparing outcomes from the best alternative use of budgets or actions in decision making) and more recently net benefit criteria (relative valuing of effects at a threshold value less costs) have been key concepts and metrics applied toward making such decisions. In an ideal world, opportunity cost and net benefit criteria should be mutually supportive and consistent. However, that requires a threshold value to align net benefit with opportunity cost assessment. This perspective piece shows that using the health shadow price as the ICER threshold aligns net benefit and opportunity cost criteria for joint adoption and financing actions that arise when reimbursing any new strategy or technology under a constrained budget. For an investment strategy with ICER at the health shadow price Bc = 1/(1/n + 1/d-1/m), net benefit of reimbursing (adopting and financing) that strategy given an incremental cost-effectiveness ration (ICER) of actual displacement, d, in financing, is shown to be equivalent to that of the best alternative actions, the most cost-effective expansion of existing programs (ICER = n) funded by the contraction of the least cost-effective programs (ICER = m). Net benefit is correspondingly positive or negative if it is below or above this threshold. Implications are discussed for creating pathways to optimal public health decision-making with appropriate incentives for efficient displacement as well as for adoption actions and related research.
引用
收藏
页数:6
相关论文
共 45 条
[1]  
[Anonymous], 2020, WHO
[2]  
[Anonymous], 2007, Global age-friendly cities: A guide
[3]  
[Anonymous], 2017, Tackling NCDs: best buys and other recommended interventions for the prevention and control of noncommunicable deseases
[4]   Rationing - How much will Herceptin really cost? [J].
Barrett, Ann ;
Roques, Tom ;
Small, Matthew ;
Smith, Richard D. .
BRITISH MEDICAL JOURNAL, 2006, 333 (7578) :1118-1120A
[5]   COST-EFFECTIVENESS UTILITY ANALYSES - DO CURRENT DECISION RULES LEAD US TO WHERE WE WANT TO BE [J].
BIRCH, S ;
GAFNI, A .
JOURNAL OF HEALTH ECONOMICS, 1992, 11 (03) :279-296
[6]  
Claxton K., 2013, working paper 82
[7]   Value based pricing for NHS drugs: an opportunity not to be missed? [J].
Claxton, Karl ;
Lindsay, Andrew Briggs ;
Buxton, Martin J. ;
Culyer, Anthony J. ;
McCabe, Christopher ;
Walker, Simon ;
Sculpher, Mark J. .
BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7638) :251-254
[8]  
Culyer Anthony, 2007, J Health Serv Res Policy, V12, P56, DOI 10.1258/135581907779497567
[9]  
Davis K., 2014, Commonwealth Fund pub, V1755
[10]  
Eckermann S., 2017, Health Economics From Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives, P279